Article
Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.
Pharmacogenetics and genomics - 1 May 2017
Hamadeh Issam S, Klinker Kenneth P, Borgert Samuel J, Richards Ashley I, Li Wenhui, Mangal Naveen, Hiemenz John W, Schmidt Stephan, Langaee Taimour Y, Peloquin Charles A, Johnson Julie A, Cavallari Larisa H
Abstract excerpt
OBJECTIVES: Voriconazole, a first-line agent for the treatment of invasive fungal infections (IFIs), is metabolized by CYP2C19. A significant proportion of patients fail to achieve therapeutic trough concentrations with standard weight-based voriconazole dosing, placing them at increased risk for treatment failure, which can be life threatening. We sought to test the association between the CYP2C19 genotype and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
